Ipsen SA, of Paris, said the results of the ELECT Phase III trial testing Somatuline Autogel/Somatuline Depot (lanreotide) showed a statistically significant reduction vs. placebo in the number of days in which immediate-release octreotide was used as a rescue medication, representing a mean difference of -14.8 percent (p = 0.017).